Scholarlink

Introduction <p>To evaluate visual and anatomical outcomes after switching to faricimab in Singaporean patients with diabetic macular edema (DME) previously treated with other anti‑vascular endothelial growth factor (VEGF) agents or therapies.</p> Methods <p>This was a retrospective single-center cohort study with chart review. The subjects were patients with DME at the Singapore National Eye Centre who had a&#xa0;suboptimal response to prior therapy and therefore switched to faricimab between 2022 and 2024; all received three or four consecutive intravitreal faricimab injections on the basis of the treating physician’s clinical decision. We analyzed changes in best available visual acuity (BAVA; ETDRS letters) and central subfield thickness (CST) on optical coherence tomography (OCT) from baseline to the first follow-up after the loading of faricimab. The initial loading regimen, consisting of three or four consecutive intravitreal faricimab injections, was determined by the treating clinician. We also conducted a subgroup analysis comparing outcomes between the three-injection and four-injection groups.</p> Results <p>A total of 157 eyes from 131 patients were included, comprising 101 eyes in the three-injection group and 56 eyes in the four-injection group. The median duration of prior therapy was 1.8&#xa0;years (interquartile range [IQR] 3.6). Mean BAVA improved significantly from 57.8 ± 16.5 to 62.4 ± 15.0 ETDRS letters at mean final follow-up of 6.9&#xa0;weeks (<i>p</i> &lt; 0.001). Mean CST decreased from 431.4 ± 129.4&#xa0;µm to 334.2 ± 90&#xa0;µm (<i>p</i> &lt; 0.001). No significant differences in BAVA change (<i>p</i> = 0.39) or CST change (<i>p</i> = 0.58) were observed between the three‑ and four‑injection groups.</p> Conclusion <p>Switching to faricimab resulted in significant short-term improvements in both visual acuity&#xa0;and retinal thickness even among patients with chronic DME who were previously receiving long-term treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-World Outcomes After Switching to Faricimab in Patients with Chronic Diabetic Macular Edema at a Tertiary Eye Center in Singapore

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月31日

查看全文
  • Kanae Fukutsu,
  • Rose Ann Goh,
  • Fang Zheng,
  • Charles Ong,
  • Anna C. S. Tan,
  • Gemmy C. M. Cheung,
  • Beau Fenner,
  • Chan Hiok Hong,
  • Choi mun Chan,
  • Ranjana Muthur,
  • Chris Sun,
  • Farrah Ibrahim,
  • Wiryasaputra Shaan,
  • Gavin S. W. Tan

摘要

Introduction

To evaluate visual and anatomical outcomes after switching to faricimab in Singaporean patients with diabetic macular edema (DME) previously treated with other anti‑vascular endothelial growth factor (VEGF) agents or therapies.

Methods

This was a retrospective single-center cohort study with chart review. The subjects were patients with DME at the Singapore National Eye Centre who had a suboptimal response to prior therapy and therefore switched to faricimab between 2022 and 2024; all received three or four consecutive intravitreal faricimab injections on the basis of the treating physician’s clinical decision. We analyzed changes in best available visual acuity (BAVA; ETDRS letters) and central subfield thickness (CST) on optical coherence tomography (OCT) from baseline to the first follow-up after the loading of faricimab. The initial loading regimen, consisting of three or four consecutive intravitreal faricimab injections, was determined by the treating clinician. We also conducted a subgroup analysis comparing outcomes between the three-injection and four-injection groups.

Results

A total of 157 eyes from 131 patients were included, comprising 101 eyes in the three-injection group and 56 eyes in the four-injection group. The median duration of prior therapy was 1.8 years (interquartile range [IQR] 3.6). Mean BAVA improved significantly from 57.8 ± 16.5 to 62.4 ± 15.0 ETDRS letters at mean final follow-up of 6.9 weeks (p < 0.001). Mean CST decreased from 431.4 ± 129.4 µm to 334.2 ± 90 µm (p < 0.001). No significant differences in BAVA change (p = 0.39) or CST change (p = 0.58) were observed between the three‑ and four‑injection groups.

Conclusion

Switching to faricimab resulted in significant short-term improvements in both visual acuity and retinal thickness even among patients with chronic DME who were previously receiving long-term treatment.